Burlington Hotel

The Burlington HC Research Group (BHCRG) is a biotechnology company dedicated to the development of advanced radioprotective therapeutics. The company's unique history is tied to the Burlington Hotel in Washington, D.C., whose legacy and assets were transitioned into a research-focused entity to fund pharmaceutical discovery. BHCRG focuses on a second-generation family of phosphorothioate drugs, a class of compounds originally investigated by the U.S. military for their potential to protect biological tissues from ionizing radiation. The company's research aims to optimize these compounds by reducing toxicity and improving metabolic stability, targeting applications in medical countermeasures and radiation safety. Its lead drug candidates, known as the BRG family, are currently in the pre-clinical testing phase.